No single finding fully captures whether donor lungs may function effectively after transplantation. Clinicians compare the donor’s medical history with oxygenation measurements, chest imaging, bronchoscopy findings, and microbiological results. This integrated approach helps distinguish adequate function from reversible abnormalities, infection, or structural damage, supporting a more informed decision than any isolated measurement could provide.
Oxygenation measurements provide information about how effectively the lungs support gas exchange, while chest imaging reveals structural or radiographic abnormalities. Interpreted together, these findings help clinicians judge whether impaired function may reflect potentially reversible changes or more significant damage. Their combined use also contributes to decisions about suitability and the level of concern before transplantation.
Bronchoscopy permits direct evaluation of the airways and can reveal airway findings that are not fully apparent from imaging alone. Microbiological testing adds information about possible infection. Together, these assessments help identify conditions that could affect recipient safety, clarify abnormalities found during the broader evaluation, and support planning for lungs that may still be considered under selected circumstances.
An abnormal finding does not automatically determine that lungs must be declined. Clinicians consider whether the problem appears reversible, how it relates to overall function, and whether the lungs can be used selectively. This reasoning is especially relevant for extended-criteria donors, whose organs may broaden the transplant pool when the potential benefits and risks are judged acceptable.
The process begins with review of the donor’s medical history, followed by assessment of oxygenation and chest imaging. Clinicians then examine the airways through bronchoscopy and obtain microbiological information when indicated by the evaluation. Findings are integrated to characterize function, infection, reversible abnormalities, and structural damage before the team decides whether to accept, decline, or selectively use the lungs.
Results help the transplant team choose among accepting the lungs, declining them, or using selected organs rather than making an all-or-none decision. The findings also identify issues that may require attention around the operation, supporting perioperative planning. By matching the assessment to recipient safety and expected graft function, clinicians can potentially expand access without ignoring important risks.